David A Katz

David A Katz

Sparrow Pharmaceuticals, Portland, Oregon, USA
orcid

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 1999 in Nature Genetics
Verified
Journal Article
Closed access
JDJeffrey M. Drazen
Jeffrey M. Drazen
CYChandri N. Yandava
Chandri N. Yandava
LDLouise Dubé
Louise Dubé
NSNatalie Szczerback
Natalie Szczerback
RHRichard Hippensteel
Richard Hippensteel
JDJeffrey Drajesk
Jeffrey Drajesk

7 February 2006 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
David A KatzDavid A Katz
David A Katz
RCRobert Carr
Robert Carr
DGDavid R Grimm
David R Grimm
HXHao Xiong
Hao Xiong
RHRhonda Holley-Shanks
Rhonda Holley-Shanks
RKRichard B Kim
Richard B Kim

1 August 1992 in Journal of Virology
Verified
Journal Article
Closed access
MCM Carey
M Carey
JKJ Kolman
J Kolman
David A KatzDavid A Katz
David A Katz
LGL Gradoville
L Gradoville
LBL Barberis
L Barberis
GMG Miller
G Miller
ZEBRA is an Epstein-Barr virus (EBV) transcriptional activator that mediates a genetic switch between the latent and lytic states of the virus by binding to the promoters of genes involved in lytic DNA replication and activating their transcription. A computer survey revealed that 9 of 23 potential or known ZEBRA-responsive EBV genes contained two or more upstream binding sites; this suggested that ZEBRA can stimulate transcription synergistically. By using a series of synthetic promoters bearing one, two, three, five, and seven upstream recognition sites, we showed that ZEBRA activates transcription synergistically when templates bearing multiple sites were compared with a template bearing a single site. This phenomenon was observed in both uninfected and EBV-infected B-lymphoid cells and in vitro in a HeLa cell nuclear extract. DNase I footprinting was used to show that the synergy was not due to cooperative DNA binding mediated by direct contact between ZEBRA dimers. The in vitro experiments revealed two manifestations of synergy. One was seen when the levels of transcription observed with the same amounts of ZEBRA added to templates bearing different numbers of sites were compared. The other was observed when the two lowest concentrations of ZEBRA that stimulated measurable transcription from any given template were compared. On the basis of both the number of sites and the calculated Kd of ZEBRA for a single site, we estimated that the critical concentration of ZEBRA needed to elicit transcriptional synergy corresponds to a site occupancy of two or three bound ZEBRA dimers. Our results have biologic implications for both the EBV lytic cycle and other processes in which the concentration of an activator changes either temporally or spatially.

23 September 2016 in Neuropsychopharmacology
Verified
Journal Article
Open access
PDF file
MRMegan L Ryan
Megan L Ryan
DFDaniel E Falk
Daniel E Falk
JFJoanne B Fertig
Joanne B Fertig
BRBeatrice Rendenbach-Mueller
Beatrice Rendenbach-Mueller
David A KatzDavid A Katz
David A Katz
RLRaye Z Litten
Raye Z Litten
Alcohol use disorder has been linked to dysregulation of the brain stress systems, producing a negative emotional state leading to chronic relapsing behavior. Vasopressin receptors appear to have a regulatory role in stress, anxiety, and alcohol. This study evaluated the novel compound, ABT-436, a V1b receptor antagonist, in alcohol-dependent participants in a 12-week clinical trial. Men and women (n=150) who met criteria for DSM–IV alcohol dependence were recruited across four sites. Participants received double-blind ABT-436 or placebo, and a computerized behavioral intervention. ABT-436 was titrated to 800 mg/day during weeks 2–12. Although the primary outcome, percentage of heavy drinking days, was lower in participants receiving ABT-436 compared with placebo, this difference was not statistically significant (31.3 vs 37.6, respectively; p=0.172; d=0.20). However, participants receiving ABT-436 had significantly greater percentage of days abstinent than those receiving placebo (51.2 vs 41.6, respectively; p=0.037; d=0.31). No significant differences were found between treatment groups on any other measures of drinking, alcohol craving, or alcohol-related consequences. Smokers receiving ABT-436 smoked significantly fewer cigarettes per week than those receiving placebo (p=0.046). ABT-436 was well tolerated, with diarrhea (mild-to-moderate severity) being the most common side effect. In subgroup analyses, participants with relatively higher baseline levels of stress responded better to ABT-436 than placebo on select drinking outcomes, suggesting there may be value in testing medications targeting the vasopressin receptor in high stress, alcohol-dependent patients.

1 January 1994 in Nucleic Acids Research
Verified
Journal Article
Closed access
David A KatzDavid A Katz
David A Katz
NTN G Theodorakis
N G Theodorakis
DCD W Cleveland
D W Cleveland
TLT Lindsten
T Lindsten
CTC B Thompson
C B Thompson
The 3'-untranslated regions of many labile transcripts contain AU-rich sequences that serve as cis determinants of mRNA stability and translational efficiency. Using a photocrosslinking technique, our laboratory has previously defined three cytoplasmic RNA-binding activities specific for the AUUUA multimers found in the 3'-untranslated regions of lymphokine mRNAs. One of these activities, AU-A, has an apparent molecular mass of 34 kDa, is constitutively expressed in both primary T cells and the Jurkat T cell leukemia line, and binds to a variety of U-rich RNA sequences. Previous studies had shown that AU-A is more prevalent in the nucleus than the cytoplasm, raising the possibility that AU-A is really a nuclear RNA-binding activity that is found in cytoplasmic extracts because of nuclear leakage during cell fractionation. We now show that AU-A shuttles between the cytoplasm and the nucleus. Our results indicate that AU-A is a candidate protein component of ribonucleoprotein complexes that participate in nucleocytoplasmic transport of mRNA and cytoplasmic mRNA metabolism. The properties of AU-A activity are similar to those of heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1). However, using monoclonal antibodies to hnRNP A1 and protease digestion patterns, we show that AU-A activity and hnRNP A1 protein are distinct. These studies have also allowed us to define a fourth RNA-binding activity of apparent molecular mass 41 kDa with specificity for AUUUA multimers. This activity is restricted to the nucleus and contains the hnRNP C protein.

15 September 2009 in International Journal of Neuropsychopharmacology
Verified
Journal Article
Open access
PDF file
AGAriel Graff-Guerrero
Ariel Graff-Guerrero
LRLaura Redden
Laura Redden
WAWalid Abi-Saab
Walid Abi-Saab
David A KatzDavid A Katz
David A Katz
SHSylvain Houle
Sylvain Houle
SKShitij Kapur
Shitij Kapur
Dopamine D3 receptors are preferentially localized in the limbic system and midbrain, and thus may be involved in the pathophysiology of neuropsychia